NAM Use for Regulatory Application

Advancing Drug Safety with AI: From Innovation to Regulatory Acceptance

Tuesday, October 6, 2026

10:00 – 11:00 am ET / 14:00 – 15:00 UTC

Farhan Khodaee, PhD; Co-Founder & CEO of Absentia Labs

The next installment of NURA’s FDA Submissions series will feature Dr. Farhan Khodaee reviewing the recent advancements in AI-driven NAMs and their toxicology applications, validation, explainability and regulatory expectations. He will then present a case study on hepatotoxicity risk assessment using mechanistic AI which was presented to the FDA and European Medicines Agency (EMA). Visit www.pcrm.org/FDA for complete details.

REGISTER

Aplicación del ensayo de viabilidad celular OECD TG 249 en la evaluación de riesgo químico ambiental

Jueves, 15 de octubre de 2026
[Thursday, October 15, 2026]
10:00 – 11:00 am ET / 14:00 – 15:00 UTC

PRESENTADOR

Marco E. Franco, PhD; Departamento de Toxicología Ambiental del Instituto Federal de Ciencia y Tecnología Acuática, Eawag (Suize)

REGÍSTRESE

Descripción:

Este seminario web sobre la Guía de la OCDE para los Ensayos 249 (OECD TG 249), un ensayo multiparamétrico de toxicidad aguda, abordará la metodología desde sus fundamentos biológicos hasta su aplicaciónes prácticas, destacando su relevancia para la evaluación de sustancias químicas en el contexto de la evaluación de riesgos de próxima generación. Obtenga más información en www.pcrm.org/NURAenEspanol.

This webinar on OECD Test Guideline 249 (OECD TG 249)—a multiparametric acute toxicity test—will cover the methodology from its biological foundations to its practical applications, highlighting its relevance to chemical assessment within the context of next-generation risk assessment. Complete details are available at www.pcrm.org/NURAenEspanol.

NURA is developing several new in-person and virtual training opportunities, including:

• Error-Corrected Sequencing Training
• A Hands-on QSAR Training
• Validation of NAMs

Join our mailing list to get updates on our latest learning opportunities. You can also use the form to provide feedback and suggest training topics. Alternatively, you can email us with your comments and suggestions at nura [at] pcrm.org. 

We would like to feature your human-based nonanimal approach in a webinar. 

You will have the opportunity to present your method to a diverse professional audience from industry, government, NGOs, and academia, followed by an audience-led Q&A session. We are looking for:

• Case studies of NAMs that have been submitted in FDA applications.
• NAMs currently being used in regulatory applications or those that have the potential to replace animal use in regulatory applications.

Please submit your presentation title and abstract or speaker suggestion to nura [at] pcrm.org. 

Connect With Us